用四焦点全息透镜实现的PS和FPS互连网络

提出了一种用四焦点全息透镜实现的二维ＰＳ（ＰｅｒｆｅｃｔＳｈｕｆｆｌｅ）和ＦＰＳ（ＦｏｌｄｅｄＰＳ）的方法，并给出了四焦点全息透镜的设计方法及应用于二维ＰＳ和ＦＰＳ互连网络中的实验结果。     

Lipase-catalyzed resolution of 1-hydroxymethyl-2-methylferrocene

±-1-Hydroxymethyl-2-methylferrocene was optically resolved by transesterification with lipases using vinyl esters such as vinyl butyrate, vinyl caproate, vinyl octanoate and vinyl decanoate, as acyl donors.     

数字化电池分析与军事应用

通过对二次电池数字化的分析,提出数字化电池在军事应用的重要性。通过电池智能控制器件一集成现场可编程电量计PS501．实现电池的数字化。     

SED-A9C主板PS/2接口的实现

本文介绍基于EP9315处理器开发的SED-A9C主板PS/2键盘接口的实现方法,对Cirrus Logic公司发布的在Linux操作系统下的PS/2键盘驱动程序进行分析,找出相应的漏洞,并给予解决。     

PVA／PS共混改性及对拉伸性能的影响

对不同配比的聚乙烯醇／聚苯乙烯（PVA／PS）共混物进行共混改性研究。使用拉力试验机测试了PVA／PS共混物的拉伸强度,使用扫描电镜（SEM）分析试样的断口,并分析共混物的分散性及相容性。实验结果表明：PVA含量在10％以内对共混物的拉伸强度影响不大,主要表现为PS的拉伸强度;而PVA含量在10％～50％的范围内,扛伸强度明显下降,在50％时达到最小值。     

增强隔热轻量板材在冷柜吸附内胆上的应用

本文对传统的高抗冲聚苯乙烯(HIPS)吸附内胆板材结构进行优化创新设计,将原来的单层内胆结构板材,通过在挤出板材的母粒中均匀添加专用发泡制剂,并采用新型双层共挤工艺,使挤出成型的板材形成复合双层结构,一层为高光致密层,保证吸附成型后内胆表面具有高光质量效果;另一层为微气孔疏松层,无数微气孔形成的密闭气室起到增强隔热的作用,提高整机的能耗等级,低碳环保;同时疏松层密度降低,使整个板材轻量化,节省原材料,实现内胆板材成本竞争力提升。该项技术结构工艺的推广应用,对整个家电行业的3R绿色设计发展将起到巨大的推动作用。     

多孔硅的应用研究进展

多孔硅是一种新型的纳米半导体光电材料,室温下具有优异的光致发光、电致发光等特性,易与现有硅技术兼容,极有可能实现硅基光电器件等多个领域的应用．扼要论述了多孔硅在绝缘材料、敏感元件及传感器、照明材料及太阳能电池、光电器件以及作为合成其它材料的模板等多个领域内的应用进展情况,并对其发展前景作了展望。     

Fabrication of hollow and porous polystyrene fibrous membranes by electrospinning combined with freeze-drying for oil removal from water

A novel method was proposed to fabricate hollow and surface porous polystyrene (PS) fibrous membranes for the removal of oil from water. Spinning solutions were prepared by using camphene and tetraethoxysilane (TEOS) as pore-forming agents, and hollow PS fibers with 100–400 nm pores on the surface were fabricated by electrospinning and freeze-drying. The distribution and volatilization of camphene and TEOS, as well as the drying behavior of solvents in high relative humidity, were important factors in forming the porous structure of PS fibers. The specific surface area of obtained PS fibrous membranes was twice that of conventional electrospun PS fibrous membranes and displayed superhydrophobic properties. Moreover, the large adsorption storage space was formed due to the hollow structure and porous surface of PS fibers. The maximum oil adsorption capacity of the porous PS fibrous membrane was 105.4 g g⁻¹, and was larger than that of the conventional PS fibrous membrane after repeated five times, thus making it a promising tool for oil spill cleanups. © 2018 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2019 , 136, 47262.     

Anti-Inflammatory Treatment with FTY720 Starting after Onset of Symptoms Reverses Synaptic Deficits in an AD Mouse Model

Therapeutic approaches providing effective medication for Alzheimer’s disease (AD) patients after disease onset are urgently needed. Previous studies in AD mouse models suggested that physical exercise or changed lifestyle can delay AD-related synaptic and memory dysfunctions when treatment started in juvenile animals long before onset of disease symptoms, while a pharmacological treatment that can reverse synaptic and memory deficits in AD mice was thus far not identified. Repurposing food and drug administration (FDA)-approved drugs for treatment of AD is a promising way to reduce the time to bring such medication into clinical practice. The sphingosine-1 phosphate analog fingolimod (FTY720) was approved recently for treatment of multiple sclerosis patients. Here, we addressed whether fingolimod rescues AD-related synaptic deficits and memory dysfunction in an amyloid precursor protein/presenilin-1 (APP/PS1) AD mouse model when medication starts after onset of symptoms (at five months). Male mice received intraperitoneal injections of fingolimod for one to two months starting at five to six months. This treatment rescued spine density as well as long-term potentiation in hippocampal cornu ammonis-1 (CA1) pyramidal neurons, that were both impaired in untreated APP/PS1 animals at six to seven months of age. Immunohistochemical analysis with markers of microgliosis (ionized calcium-binding adapter molecule 1; Iba1) and astrogliosis (glial fibrillary acid protein; GFAP) revealed that our fingolimod treatment regime strongly down regulated neuroinflammation in the hippocampus and neocortex of this AD model. These effects were accompanied by a moderate reduction of Aβ accumulation in hippocampus and neocortex. Our results suggest that fingolimod, when applied after onset of disease symptoms in an APP/PS1 mouse model, rescues synaptic pathology that is believed to underlie memory deficits in AD mice, and that this beneficial effect is mediated via anti-neuroinflammatory actions of the drug on microglia and astrocytes.